Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma, Large B-Cell, Diffuse 416Lymphoma 406Lymphoma, Non-Hodgkin 344Leukemia, Lymphocytic, Chronic, B-Cell 313Lymphoma, Follicular 301Lymphoma, Mantle-Cell 226Lymphoma, B-Cell, Marginal Zone 161Leukemia 119Lymphoma, B-Cell 112Burkitt Lymphoma 110Waldenstrom Macroglobulinemia 99Precursor Cell Lymphoblastic Leukemia-Lymphoma 90Recurrence 85Hodgkin Disease 60Lymphoma, Large-Cell, Immunoblastic 57Neoplasms 39Multiple Myeloma 26Lymphoma, Large-Cell, Anaplastic 26Myelodysplastic Syndromes 25Leukemia, Myeloid, Acute 24Hematologic Neoplasms 22Dendritic Cell Sarcoma, Interdigitating 22Leukemia, Hairy Cell 20Intraocular Lymphoma 17Leukemia, Prolymphocytic 16Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 14Lymphoma, T-Cell 14Neoplasms, Plasma Cell 13Hematologic Diseases 13Lymphoproliferative Disorders 12

Interventions

Dexamethasone 3iniparib 2Ultrasonography 2Poly(ADP-ribose) Polymerase Inhibitors 2Calcium Dobesilate 2Blood Specimen Collection 2tislelizumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1asparaginase erwinia chrysanthemi recombinant 1amminedichloro(2-methylpyridine)platinum(II) 1ZD4054 1Vincristine 1Sodium Chloride 1Rituximab 1Paclitaxel 1Narrow Band Imaging 1Methotrexate 1Mammography 1Lenalidomide 1Immune Checkpoint Inhibitors 1High-Energy Shock Waves 1Doxorubicin 1Dexrazoxane 1Cytarabine 1Cetirizine 1Carboplatin 1BNT162 Vaccine 1Asparaginase 12019-nCoV Vaccine mRNA-1273 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypersensitivity × Rituximab × Clear all
NCT01206777 2017-12-20

Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
52 enrolled 4 charts

Hypersensitivity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡